Track Rubicon Research Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 2.11 %
Low
1,735.4
High
1,870.0
1 Month returns: 19.79 %
Low
1,544.7
High
1,899.0
1 Year returns: –
3 Year CAGR: –
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Rubicon Research Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Rubicon Research Ltd. Shareholding Pattern
Quarterly breakdown of Rubicon Research Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Rubicon Research Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Rubicon Research Ltd.?
The current share price of Rubicon Research Ltd. is ₹ 1,860.60 as of 8 Sep 2026.
What is the market capitalisation of Rubicon Research Ltd.?
The market capitalisation of Rubicon Research Ltd. stands at ₹ 30,798.90 Cr.
What is the PE ratio of Rubicon Research Ltd.?
The Price-to-Earnings (PE) ratio of Rubicon Research Ltd. is 106.86 as of the latest trailing twelve months data.
What is the ROE and ROCE of Rubicon Research Ltd.?
Rubicon Research Ltd. has a Return on Equity (ROE) of 26.97% and a Return on Capital Employed (ROCE) of 27.75% as per the latest financial reports.
What is the 52-week high and low of Rubicon Research Ltd.?
The 52-week high of Rubicon Research Ltd. is - and the 52-week low is -.
What is the dividend yield of Rubicon Research Ltd.?
The dividend yield of Rubicon Research Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Rubicon Research Ltd.?
Foreign Institutional Investors (FII) hold 7.52%, Domestic Institutional Investors (DII) hold 7.41% and retail/public investors hold 23.13% of Rubicon Research Ltd. shares.
What sector does Rubicon Research Ltd. belong to?
Rubicon Research Ltd. operates in the Healthcare sector.
What is the beta of Rubicon Research Ltd.?
The beta of Rubicon Research Ltd. is -, indicating its price volatility relative to the broader market.
What is the RSI of Rubicon Research Ltd.?
The 14-day Relative Strength Index (RSI) of Rubicon Research Ltd. is 64.17, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Rubicon Research Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 71.5 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
71.5 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 9.34% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
Not enough data
Strong revenue growth and above median growth of industry
The company delivered strong revenue growth of 46.65% for 12-month ended 30 Jun 2026 and the growth was 36.06 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 10.59
Value 46.65
-99.6111701.8
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 78.47% for 12-month ended 30 Jun 2026 and the growth was 71.27 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low and declining Debt to Equity
The company has low Debt to Equity of 0.24 as on 30 Jun 2026 and Debt to Equity decreased by 0.68 in the last 1 year
What is Debt to Equity?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 106.86 indicates that the stock is expensive on a standalone basis and is at a 236.25% premium to industry median P/E
What is P/E Ratio?
Median: 31.78
Value 106.86
-0.96721.13
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
High ROE but declining trend
The company reported strong ROE of 26.97% for 12-month ended 30 Jun 2026 but ROE declined by -325 bps from 1 year ago
What is ROE (FY)?
High operating margin but declining trend
The company reported strong operating margin of 20.64% for 12-month ended 30 Jun 2026 but operating margin declined by -222 bps from 1 year ago
What is Operating profit margin?
Company's earnings are of moderate quality
Earnings quality score of 46.6 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
46.6 / 100
Stock in ASM list
The stock has been places in Additional Surveillance Measure (ASM) list (LTASM - I (13)).
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Oct 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
59.99
59.99
59.86
59.76
Indian Promoter
24.02
24.02
23.97
23.93
Foreign Promoter
35.97
35.97
35.89
35.83
Institutions
19.12
17.43
17.56
16.95
Mutual Funds / UTI
5.63
6.61
7.14
7.23
FI/Bank/Insurance
2.30
0.39
0.31
0.18
Govt
-
-
-
-
FII
9.38
7.99
7.54
7.52
Other Institutions
1.82
2.44
2.57
2.02
Non-Institution
20.89
22.58
22.58
23.30
Bodies Corporate
0.01
0.27
0.23
0.17
Others (incl. Retail)
No. of shareholders
20.88
1,05,041
22.31
31,745
22.35
33,586
23.13
43,013
Corporate Actions
History of Rubicon Research Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 1.50/share
Record date: 7th Aug 2026Ex-date: 7th Aug 2026
Announced on: 29th May 2026
1,860.60111.8 (6.39%)
196.35% since 16 Oct 2025
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Overview of Rubicon Research Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.
Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage f...